Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

TRAMADOL vs TRASTUZUMAB DERUXTECAN: Which Drug Is Safer?

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

TRAMADOL vs TRASTUZUMAB DERUXTECAN: Safety Overview

Metric TRAMADOL TRASTUZUMAB DERUXTECAN
Total FAERS Reports 75,664 2,684
Deaths Reported 14,555 653
Death Rate 19.2% 24.3%
Hospitalizations 19,235 780
Average Patient Age 50.7 yrs 56.5 yrs
% Female Patients 55.6% 91.9%
FDA Approval Date Apr 4, 2024 N/A
Manufacturer Vertical Pharmaceuticals, LLC Daiichi Sankyo Inc.
Route ORAL INTRAVENOUS
Marketing Status Discontinued N/A